Table 1.

Prostate cancer tissues used for methylation microarray analysis

NonrecurrentBiochemical recurrenceLocal recurrenceSystemic recurrence
Number of patients75434436
Age, y62.61 ± 8.0464.04 ± 5.9563.31 ± 6.0364.41 ± 7.57
Preoperative PSA, ng/mL
 <417 (22.6)1 (2.3)2 (4.5)3 (8.3)
 4–1045 (60)22 (51.1)19 (43.1)13 (36.1)
 >1012 (16)17 (39.5)15 (34.09)15 (13.8)
 n.a.19 (1.3)3 (6.9)8 (18.1)5 (13.8)
Gleason score
 623 (30.6)4 (9.3)3 (6.8)0
 734 (45.3)19 (44.1)27 (61.3)11 (30.5)
 88 (10.6)8 (18.6)6 (13.6)5 (13.8)
 910 (13.3)12 (27.9)8 (18.1)15 (41.6)
 100005 (13.8)
TNM
 T2a19 (25.3) [4]7 (16.2) [1]11 (25) [3]1 (2.7)
 T2b30 (40) [16]14 (32.5) [3]16 (36.3) [9]6 (16.6) [4]
 T3a20 (26.6) [11]10 (23.2) [7]8 918.1) [4]12 (33.3) [5]
 T3b6 (8) [3]12 (27.9) [9]7 (15.9) [3]11 (30)[7]
 T4002 (4.5) [1]6 (16.6) [4]
Ploidy
 Diploid38 (50.6)19 (44.1)17 (38.6)15 (41.6)
 Tetraploid29 (38.6)19 (44.1)22 (50)13 (36.1)
 Aneuploid8 (10.6)5 (11.6)5 (11.3)8 (22.2)
GPSM score
 <1047 (62.2)15 (34.8)10 (22.7)6 (16.6)
 10–1222 (29.3)14 (32.5)20 (45.4)14 (38.8)
 >125 (6.6)11 (25.5)6 (13.6)12 (33.3)
 n.a.1 (1.3)3 (6.9)8 (18.2)5 (13.8)
PSA progression, y02.33 ±1.770.77 ± 0.421.39 ± 1.54
Local progression, y002.31 ± 1.183.27 ± 2.99
Systemic progression, y0002.59 ±3.41
Follow-up, y6.25 ± 1.485.87 ± 1.414.31 ± 1.694.43 ± 3.97
Prostate death0006
Other death0627

NOTE: Mean ± S.D are shown for age, years for PSA, local, and systemic progression and follow-up years of patients with prostate cancer. Value in parentheses indicates the percentage of cases representing the group. Value in square brackets indicates the node-positive cases. Matched normal tissues from 40 patients [age (mean ± SD) = 63.15 ± 7.28] were used.

Abbreviation: n.a., not available.